A Mutant Ahr Allele Protects the Embryonic Kidney from Hydrocarbon-Induced Deficits in Fetal Programming by Nanez, Adrian et al.
Environmental Health Perspectives  •  v o l u m e  119 | n u m b e r 12 | December 2011  1745
Research
Embryonic develop  ment requires the orches­
tration of temporally precise genetic events 
that culminate in formation of a complete 
organism and that respond to diverse environ­
mental and somatic signals in utero. Previous 
studies identified the aryl hydrocarbon recep­
tor (AHR) as an important nuclear transcrip­
tion factor during mammalian embryogenesis 
and throughout maturity. Ligand­activated 
AHR interacts with hypoxia­inducible fac­
tor 1β (HIF1β) to form transcriptional com­
plexes that bind specific DNA sequences to 
regulate genetic targets (Denison and Nagy 
2003). Nuclear translocation triggers proteo­
lytic degradation of AHR protein, a signaling 
event that defines the biologi  cal responsive­
ness to AHR ligands (Roberts and Whitelaw 
1999). AHR protein is highly polymorphic 
in the core ligand­binding and trans  activa  tion 
domains, and this variability dictates differ­
ences in susceptibility to environ  mental injury 
in mice (Moriguchi et al. 2003) and humans 
(Sasaki et al. 2006).
AHR participates in develop  mental regula­
tion of vascular structures in liver (Fernandez­
Salguero et al. 1995; Lahvis et al. 2005; 
Schmidt et al. 1996), as well as morpho  genesis 
of heart (Lund et al. 2003, 2006) and kidney 
(Falahatpisheh and Ramos 2003; McMillan 
and Bradfield 2007). A role for AHR in renal 
develop  ment was firmly established in experi­
ments showing that Ahr­null mice exhibit 
deficits in renal condensation, appearance 
of differentiated structures, and cellular pro­
liferation (Falahatpisheh and Ramos 2003). 
The kidney derives from the nephric ridge of 
the inter  mediate meso  derm where the pro­
nephric duct elongates to form the Wolffian 
duct, which in turn gives rise to the ureteric 
bud and sets the stage for condensation of 
metanephric mesenchyme and mesynchemal­
to­epithelial cell transition. Wilms’ tumor 
suppressor gene (Wt1) functions as a criti­
cal regulator of nephro  genesis by encoding a 
Cis2­His2 zinc­finger protein that functions 
via transcriptional regulation of insulin­like 
growth factor 2 (Igf2r), syndecan­1 (Sdc1), 
epidermal growth factor receptor (Egfr), and 
retinoic acid receptor, alpha (Rarα), among 
other targets (Avner 1993; Hosono et al. 
1999). Homozygous Wt1–/– mice do not 
undergo differentiation from pro  nephros to 
metanephros and die in utero (Kreidberg et al. 
1993). Wt1 activity can be regulated in cis by 
the different ratios of its own splice variants 
and in trans by proteins such as bone marrow 
zinc finger 2 (BMZF2) (Lee et al. 2002). The 
most studied regulatory mechanism of Wt1 
involves the formation of +KTS and –KTS 
splice variants. KTS splice variants originate 
from the insertion of a lysine­threonine­ser­
ine between the third and fourth zinc fingers, 
and this change regulates Wt1 DNA binding 
specificity (Menke et al. 1998). In humans, 
reduced WT1 +KTS mRNA isoforms result 
in severe kidney and gonad develop  mental 
deficits, known as Frasier syndrome (Barbaux 
et al. 1997). Changes in exon 5 splice vari­
ants are also associated with deficits in renal 
differentia  tion (Iben and Royer­Pokora 1999). 
Addition of 17 amino acids in exon 5 creates 
an mRNA isoform (17aa) that regulates trans­
activation (Wang et al. 1995). N­terminal 
residues 1–182 encode a dimerization 
region implicated in the regulatory mecha­
nism exerted by dominant negative mutants 
(Englert et al. 1995).
The precise mechanism by which AHR 
regulates genetic elements during nephro­
genesis is not known. Given the requisite 
activation of AHR by endogenous or exoge­
nous ligands, it is likely that develop  mental 
regulatory functions of AHR involve tran­
scriptional regulation of genes during early 
kidney morpho  genesis. The polymorphic 
nature of the AHR locus suggests that the 
inherent susceptibility of mice and humans to 
develop  mental interference by AHR ligands 
is variable. Such relationships can be studied 
taking advantage of murine models express­
ing variant AHR proteins that structurally 
and functionally resemble those in humans. 
The C57BL/6J (C57) mouse is perhaps the 
most widely used mouse model to evaluate the 
biology of AHR (Moriguchi et al. 2003). This 
strain is naturally sensitive to exogenous AHR 
ligands, as evidenced by trans  regulation of 
AHR­regulated genes (Moriguchi et al. 2003). 
In contrast, B6.D2N­Ahrd/J (D2N) mice are 
highly resistant to ligand­mediated AHR acti­
vation and gene transactivation. The C57 and 
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Ba c k g r o u n d: The use of experimental model systems has expedited the elucidation of pathogenetic 
mechanisms of renal developmental disease in humans and the identification of genes that orchestrate 
developmental programming during nephro  genesis.
oBjectives: We conducted studies to evaluate the role of AHR polymorphisms in the disruption of 
renal developmental programming by benzo(a)pyrene (BaP).
Me t h o d s : We used metanephric cultures of C57BL/6J (C57) mice expressing the Ahrb-1 allele and 
B6.D2N‑Ahrd/J (D2N) mice expressing a mutant allele deficient in ligand binding (Ahrd) to inves‑
tigate molecular mechanisms of renal development. Deficits in fetal programming were evaluated in 
the offspring of pregnant mice treated with BaP during nephro  genesis.
re s u l t s: Hydrocarbon challenge of metanephri from C57 mice altered Wilms’ tumor suppres‑
sor gene (Wt1) mRNA splice variant ratios and reduced mRNAs of the Wt1 transcriptional targets   
syndecan‑1 (Sdc1) paired box gene 2 (Pax2), epidermal growth factor receptor (Egfr), and retinoic 
acid receptor, alpha (Rarα). These changes correlated with down‑regulation of effectors of differentia‑
tion [secreted frizzled‑related sequence protein 1 (Sfrp1), insulin‑like growth factor 1 receptor (Igf1r), 
wingless‑related MMTV‑integration site 4 (Wnt4), Lim homeobox protein 1 (Lhx1), E‑cadherin]. 
In contrast, metanephri from D2N mice were spared hydrocarbon‑induced changes in Wt1 splice 
variant ratios and deficits of differentiation. We observed similar patterns of dys  morpho  genesis and 
progressive loss of renal function at postnatal weeks 7 and 52 in the offspring of pregnant C57 but 
not D2N mice gavaged with 0.1 or 0.5 mg/kg BaP on gestation days 10–13.
co n c l u s i o n s: These findings support a functional link between AHR and WT1 in the regulation 
of renal morpho  genesis and raise important questions about the contribution of human AHR poly‑
morphisms to the fetal origins of adult‑onset kidney disease.
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D2N mice are isogenic strains that differ in 
AHR ligand­binding affinity due to a single 
nucleo  tide substitution that replaces valine for 
alanine at codon 375 in the ligand­binding 
domain, resulting in a 10­fold reduction in 
ligand­binding affinity (Poland et al. 1994). 
Humans predominantly express an AHR 
protein of reduced ligand­binding affinity 
similar to that in D2N mice, with several poly­
morphic variants identified to date that exhibit 
increased ligand­binding affinities and trans­
activation potentials (Sasaki et al. 2006). Some 
of these variants afford heightened suscepti­
bility to cancer, and possibly develop  mental 
interference. We conducted the present study 
to evaluate the impact of polymorphic variants 
of the AHR on hydrocarbon­induced deficits 
in nephro  genesis. We present evidence that a 
mutant Ahr allele deficient in ligand­binding 
affinity and nuclear transactivation protects the 
developing murine kidney from hydrocarbon­
induced deficits of fetal genetic programming 
and loss of renal function in adult life. These 
findings implicate AHR in the regulation of 
renal develop  mental programming and the 
fetal basis of adult­onset kidney disease.
Materials and Methods
Metanephric cultures. On gestation day 
(GD) 11.5, mouse embryos were dissected 
from C57BL/6J Ahrb-1/b-1 wild­type and 
B6.D2N­Ahrd/d/J mice (Jackson Laboratories, 
Bar Harbor, ME). All animals were treated 
humanely and with regard for allevia­
tion of suffering. Metanephri were cultured 
on 0.45­mm polyethylene terephthalate 
cyclopore cell culture inserts (Fisher Scientific, 
Pittsburgh, PA) for 1–4 days. Kidney explants 
were maintained at the liquid–gas interface 
in a solution consisting of a 1:1 mixture of 
Dulbecco’s modified Eagle’s medium and F12 
medium supplemented with 10% fetal bovine 
serum and a 5× concentration of MITO 
serum extender (Becton Dickenson, Bedford, 
MA). Explants were equilibrated for 1 day 
before start of experi  ments. Seven or more kid­
ney explants from four dams were placed on 
individual inserts and exposed daily to 3 μM 
benzo(a)pyrene (BaP) or an equivalent volume 
of dimethyl sulfoxide (DMSO), with or with­
out 20 nM α­napthoflavone (α­NF), for 1, 3, 
or 4 days. α­NF is a ligand of AHR that fails 
to induce conformational changes for efficient 
transactivation of target genes and thus func­
tions as a competitive antagonist. The dose 
of BaP tested in vitro represents an environ­
mentally relevant dose that affords optimal 
activation of AHR (Bowes and Ramos 1994). 
Explants were fixed in situ and processed for 
further evaluation.
Intrauterine exposures to BaP. Timed­
pregnant C57BL/6J Ahrb-1/b-1 and B6.D2N­
Ahrd/d/J mice were gavaged on GDs 10–13 
with 0.1 or 0.5 mg/kg BaP or medium­
chain triglyceride oil (MCT; Mead Johnson 
Nutritionals, Evansville, IN). MCT is a well­
characterized emulsion vehicle optimal for oral 
BaP formulations. The doses examined are 
considerably lower than those used previously 
in studies of teratogenicity (Lummus and 
Henningsen 1995; MacKenzie and Angevine 
1981; Rodriquez et al. 1999; Wells et al. 1997; 
Winn and Wells 1997) and approximate 
human exposures among at­risk populations 
when corrected for differences in ontogenic 
profiles (Menzie et al. 1992; Rebagliato et al. 
1995). One week after birth, some pups were 
euthanized and kidney, heart, liver, testis, and 
aorta were fixed in situ under physiological 
pressure; others were kept for studies of renal 
structure and function 52 weeks after birth.
Histology and morphometric analysis. 
Metanephri were fixed in 4% paraformal­
dehyde at 4°C for 16 hr, immobilized in 
Histogel (Richard Allan Scientific, Kalamazoo, 
MI), and embedded in paraffin. Serial sections 
(4 μm) were cut and stained with hematoxylin 
and eosin (H&E) for visualization of differen­
tiated structures. Images of at least five meta­
nephri per treatment group were captured 
with an Axiovert 200 inverted microscope 
(Carl Zeiss Microscopy, Thornwood, NY) and 
stored as ZVI files. Glomeruli and S­shaped 
and comma­shaped bodies were quanti­
fied using manual functions in AxioVision 
(release 4.1; Carl Zeiss Microscopy). For 
in vivo measure  ments, kidneys were fixed 
in 4% paraformaldehyde at 4°C for 12 hr 
and embedded in paraffin. Sections (5 μm) 
were cut and stained with H&E. Images of 
entire kidney cross­sections from five different 
renal planes were captured and analyzed using 
AxioVision (release 4.3) image analysis soft­
ware (Carl Zeiss Microscopy). All values were 
normalized to renal area.
Immunohistochemistry.  Slides were 
exposed under pressure to Antigen Unmasking 
Solution® (Vector Labratories, Burlingame, 
CA). Sections were incubated with Wilms 
tumor suppressor (WT1) antibody (180 amino 
acids in length; Santa Cruz Biotechnology, 
Santa Cruz, CA) or AHR rabbit polyclonal 
antibodies (Biomol International, Plymouth 
Meeting, PA) overnight at 4°C in a solution 
of 0.3% Triton­X and 5–10% goat serum. 
Primary antibodies were bound to a goat 
anti­rabbit biotinylated secon  dary antibody 
(Invitrogen­Molecular Probes, Carlsbad, 
CA), amplified with the the Vectastain Elite 
ABC Kit; Vector Laboratories), developed 
with diamino  benzidine (DAB), and counter­
stained with Mayer’s hematoxylin (Vector 
Laboratories). Threshold optimization was 
completed relative to negative controls, and 
indices of protein expression were expressed as 
sum density normalized to total area. Podocyte 
numbers were quantified using WT1 signal 
filtered for color, intensity, and size. All values 
were normalized to glomerular density.
Quantitative polymerase chain reac-
tion (PCR). Total RNA was extracted using 
TRIzol® (Invitrogen, Carlsbad, CA) and 
cDNA synthesized using Super Script II 
(Invitrogen) per manufacturer’s instructions. 
Quantitative PCR was performed to detect 
differences in the ratio of Wt1 splice variants 
(±KTS) in response to AHR ligand treatment 
(Falahatpisheh and Ramos 2003). All primers 
were designed using Beacon Designer (ver­
sion 5.1; PREMIER Biosoft, Palo Alto, CA) 
to create amplicons from 150 to 300 base 
pairs with an average melting temperature of 
55°C. All primers used are listed in Table 1. 
Urinary albumin. Individual urine sam­
ples were stored at –80°C in stabilizing buffer 
(Biotrin International, Dublin, Ireland). One 
microliter of sample was loaded onto 4–12% 
NuPAGE Bis­Tris gel (Invitrogen) under 
reducing conditions and processed for silver 
staining per the manufacturer’s specifications. 
Table 1. PCR primers used in all quantitative PCR assays.
Gene Forward primer 5´-3´ Reverse primer 5´-3´
18S CGTCTGCCCTATCAACTTTCG GCCTGCTGCCTTCCTTGG
Cytochrome P450 1A1 (Cyp1a1) TCGTGTCAGTAGCCAATGTC GCATCCAGGGAAGAGTTAGG
Taurine transporter (TauT) CATCCATCGTCATTGTGTC AAGTTGGCAGTGCTAAGG
Syndecan-1 (Sdc1) GAGAACAAGACTTCACCTTTG AGCACTTCCTTCCTGTCC
Paired box gene 2 (Pax2) AGGTTTACATCTGGTCTGG TAGGAAGGACGCTCAAAG
Epidermal growth factor receptor (Egfr) GAGGAGGAGAGGAGAACTG GGTGGGCAGGTGTCTTTG
Retinoic acid receptor, alpha (Rarα) CCCAGAAGACTAAAGTTGAC TGGCAGGTAGTTGTGATG
Secreted frizzled-related sequence protein 1 (Sfrp1) GCAGTTCTTCGGCTTCTA ATGGAGGACACACGGTTG
Insulin-like growth factor 1 receptor (Igf1r) GTCCCTCAGGCTTCATCC GAGCAGAAGTCACCGAATC
Insulin-like growth factor 2 receptor (Igr2r) AGTATGTGAACGGCTCTG TCTGTGATTGTCTGGATAGG
Wingless-related MMTV-integration site 4 (Wnt4) GTAGCCTTCTCACAGTCCTTTG GGTACAGCACGCCAGCAC
Lim homeobox protein 1 (Lhx1) ACCTAAGCAACAACTACAATC AACACGGGAGTAGAAAGC
E-cadherin CGACCCTGCCTCTGAATCC CTTTGTTTCTTTGTCCCTGTTGG
Table 2. Cyp1a1 mRNA expression.
Exposure (days)
Normalized fold change 
relative to DMSO control
C57
1 154.34 ± 20.8
2 455.09 ± 30.62
3 730.00 ± 24.00
D2N 
1 1.82 ± 0.27
2 12.44 ± 2.03
3 39.49 ± 1.20AHR signaling and nephrogenesis
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Sum density values were calibrated to mouse 
serum albumin standards ranging from 10 to 
0.001 μg/μL.
Urinary renal papillary antigen 1 (RPA1) 
and glutathione S-transferase Yb1 (GSTYb1) 
measurements. Ninety­six–well microtiter 
plates were conjugated with anti­RPA1 or 
GSTYb1 IgG. Urine was diluted 1:25 and 
equilibrated for 1 hr at room temperature 
before addition of antibody–enzyme conju­
gate. After substrate develop  ment, absorbance 
was read at 450 nm using 630 nm as a refer­
ence. Absorbance was normalized to internal 
controls and expressed as relative units.
Western blot analysis. Protein was extracted 
using T­PER reagent (Pierce, Rockford, IL) 
per the manufacturer’s specifications. Samples 
were run on 4–12% NuPAGE Bis­Tris gels 
under reducing conditions, transferred to a 
polyvinyl difluoride membrane, and probed 
with WT1(180) rabbit polyclonal antibody 
(Santa Cruz Biotechnology) and horseradish 
peroxidase–conjugated secondary antibody.
Statistical analysis. Statistical significance 
was determined as noted using Student’s t­test, 
analysis of variance (ANOVA), Wilcoxon rank 
sums, least significant difference (LSD), and 
Tukey post hoc tests at the p < 0.05 level.
Results
Deficits in metanephric differentiation 
by BaP are linked to Ahrb‑1. Metanephric 
explants of C57­Ahrb-1/b-1 and D2N­Ahrd/d 
mice were challenged with 3 μM BaP for 1, 3, 
or 4 days. Quantitative reverse­transcriptase 
PCR qRT­PCR analysis of C57 metanephri 
revealed time­dependent induction of cyto­
chrome P450 1A1 (Cyp1a1) mRNA, whereas 
D2N metanephri showed a markedly abro­
gated response (Table 2). A consecutive 
4­day exposure of C57 cultures to BaP sig­
nificantly delayed metanephric develop  ment 
(Figure 1A), as evidenced by decreased num­
bers of mature glomeruli (Figure 1B) and cor­
responding increases in comma and S­shaped 
bodies, structures indica  tive of immature 
glomerular development (Figure 1C). 
To determine whether ligand binding to 
AHR­mediated deficits in renal cell differen­
tiation, we examined effects of BaP exposure 
on D2N mice expressing the Ahrd/d allele and 
C57 mice co­treated with α­NF, a competi­
tive inhibitor at the AHR ligand­binding site. 
Activation of the low­affinity Ahrd/d recep­
tor was not associated with morphologic 
or genetic deficits in developing kidneys. 
Although α­NF slightly decreased glomerular 
density, we observed no reciprocal changes in 
the abundance of undifferentiated structures 
or alterations in gene expression (Figure 1B). 
As expected, α­NF efficiently neutralized the 
actions of BaP on metanephric differentia­
tion, as evidenced by reversal of dedifferentia­
tion deficits. Immunohistochemical analysis 
showed a decrease in AHR protein after 4 days 
of BaP exposure in Ahrb-1/b-1 mice (Figure 2), 
whereas the abundance of AHRd/d protein was 
not influenced by BaP treatment (Figure 2A). 
Instead, expression of Ahrd/d, or co­treatment 
with BaP and α­NF, prevented loss of AHR 
protein. These findings are consistent with 
the hypothesis that AHR is required for renal 
Figure 1. BaP inhibits nephro  genesis via an Ahr allele–specific mechanism, as shown by metanephric 
cultures treated with 3 µM BaP or DMSO without or with α-NF (see “Materials and Methods” for details). 
(A) Photomicrographs of C57 and D2N metanephri stained with H&E. BaP-exposed C57 metanephri display 
less morphologically distinct differentiated structures compared with the C57 DMSO control. Expression 
of the Ahrd allele in D2N mice abrogates BaP-induced deficits; co-treatment with the competitive inhibitor 
α-NF also inhibited BaP effects. Abbreviations: C, comma-shaped bodies; g, glomeruli; s, S-shaped bodies. 
Bars = 100 µm. (B and C) Quantification (mean ± SD) of glomeruli (B) and comma and S-shaped bodies (C) 
normalized to area from serial sections (n ≥ 6 metanephri/group). 
*p < 0.05 compared with the corresponding DMSO control, by ANOVA and LSD post hoc tests. 
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develop  mental signaling and that disruption 
of nephro  genesis by BaP requires AHR ligand 
binding, signaling, and protein degradation.
Next, we monitored the expression 
of mesenchymal [Sfrp1 (secreted frizzled­
related sequence protein 1)]and epithelial 
[Igf1r (  insulin­like growth factor 1 receptor), 
Wnt4 (wingless­related MMTV­integration 
site 4), Lhx1 (Lim homeobox protein 1), 
and E­cadherin] markers of differentiation 
by qRT­PCR to determine if morphologic 
deficits correlated with modulation of genetic 
targets. Markers of renal epithelial cell differ­
entiation (Igf1r, Wnt4, Lhx1, and E­cadherin) 
were modulated to variable degrees relative 
to vehicle control after BaP exposure of C57 
metanephri for 1, 3, or 4 days (Figure 3A). 
Igf1r, Wnt4, Lhx1, and E­cadherin were also 
significantly down­regulated by day 4 of 
BaP treatment in C57 cultures (Figure 3A), 
whereas Sfrp1 was down­regulated at all time 
points (Figure 3A). Metanephri expressing the 
Ahrd allele showed variable degrees of induc­
tion in Sfrp1, Igf1r, and Wnt4 throughout the 
exposure period and were completely spared 
deficits in differentiation, except for changes 
in Lhx1, which showed decreased levels at all 
time points (Figure 3B). Collectively, these 
data indicate that nephro  genic deficits induced 
by BaP require integrity of AHR signaling and 
involve inter  ference with coordinated renal cell 
differentiation programming.
Ahr allele mediates disruption of Wt1 
mRNA splice variants by BaP. BaP exposure 
of C57 metanephri for 4 consecutive days 
resulted in 3­ and 8­fold induction of +KTS 
and –KTS variants, respectively (Figure 4A,B). 
Expression of +17aa or –17aa was not altered 
by BaP (Figure 4C,D). Consistent with the 
known transcriptional repressive activity of 
WT1, significant reductions in the relative 
expression of several WT1 targets, includ­
ing Sdc1, paired box gene 2 (Pax2), Egfr, 
and Rarα, were observed by day 4 of BaP 
treatment (Figure 4E). D2N­Ahrd/d meta­
nephri exposed to 3 μM BaP did not exhibit 
changes in any of the Wt1 mRNA splice 
variants (Figure 5A–D) or Wt1 target genes 
(Figure 5E), except for Rarα, where the pat­
tern of regulation was reversed compared with 
the C57 strain. C57 but not D2N metanephri 
exhibited decreased taurine transporter (TauT) 
mRNA (compare Figures 4E and 5E).
Intrauterine exposures to BaP alter renal 
develop  ment and function of the offspring. 
Control C57 and D2N mice showed similar 
numbers of glomeruli (Figure 6A). In utero 
exposure to both 0.1 and 0.5 mg/kg BaP dur­
ing GDs 10–13 caused signifi  cant reductions in 
glomerular numbers (Figure 6). One week after 
birth, the kidneys of offspring of C57 dams 
exposed to BaP exhibited significant reductions 
in glomerular size and increased numbers of 
undifferentiated cells compared with controls 
(Figure 6B). In contrast, D2N mice expressing 
the low­affinity Ahr allele were spared BaP­
induced glomerular deficits (Figure 6). 
C57 and D2N mice exhibited similar 
amounts of urinary albumin, demonstrating 
that expression of the Ahrd allele in itself does 
not compromise renal function in unstressed 
animals (Figure 7A). Measurements of urinary 
albumin 52 weeks after intra  uterine exposure 
to BaP showed dose­dependent increases in 
urinary albumin only in C57 mice express­
ing the responsive Ahrb-1 allele, whereas 
Figure 2. AHR expression correlates with nephro  genesis, as shown by immunohistochemical analysis of 
metanephric cultures treated with 3 µM BaP or DMSO without or with α-NF (see “Materials and Methods” 
for details). Exposure to BaP decreases AHR protein levels, as indicated by DAB staining (A) and density 
(mean ± SD) of AHR normalized to total area (B). Bars = 100 µm. Protein expression was similar in DMSO-
treated C57 and D2N metanephri, but D2N and α-NF–co-treated C57 metanephri were not sensitive to 
BaP-induced deficits in AHR protein expression. 
*p < 0.05 compared with the corresponding DMSO control, by ANOVA and LSD post hoc tests. 
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D2N mice were unaffected (Figure 7A,B). 
Immunohistochemical quantification of 
podocyte numbers revealed no differences 
between C57 and D2N mice (Figure 7C). 
In utero exposure to 0.1 or 0.5 mg/kg BaP 
was associated with decreased podocyte 
numbers in 52­week­old C57 but not D2N 
mice (Figure 7C). Consistent with this find­
ing, both doses of BaP decreased WT1 protein 
expression in an Ahr allele–specific manner 
(Figure 7D). BaP exposure did not alter uri­
nary RPA1 or GSTYb1 levels in either C57 or 
D2N mice (Figure 8), suggesting that in utero 
BaP exposure was selectively associated with 
glomerular pathology and did not involve col­
lecting duct (RPA1) or distal tubular injury 
(GSTYb1) (Falkenberg et al. 1996; Hildebrand 
et al. 1999; Kilty et al. 1998).
Figure 3. BaP exposure down-regulates markers of renal cell differentiation, as shown by qRT-PCR analysis of BaP-treated C57 (A) and D2N (B) metanephric cul-
tures (see “Materials and Methods” for details). Values (mean ± SD) represent 2−∆∆CT normalized fold change rela  tive to the DMSO CF7 control (dashed line); n ≥ 6 
metanephri/group. At 4 days of BaP exposure, C57 metanephri (A) but not in D2N metanephri (B) showed significant decreases in differentiation markers. 
*p < 0.05, by Wilcoxon rank sum test. 
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Figure 4. WT1 dysregulation by BaP correlates with loss of known WT1 tar-
gets in C57 metanephri, as shown by qRT-PCR analysis (see “Materials and 
Methods” for details). Values (mean ± SD) represent 2−∆∆CT normalized fold 
change relative to the DMSO control (shown as a dashed line in E); n ≥ 6 
metanephri/group. (A–D) Abundance of splice variants from BaP-treated and 
DMSO control samples. After 4 days of BaP exposure, significant increases 
were seen in –KTS (B) compared with +KTS (A) isoforms but not in +17aa (C) 
or –17aa (D) isoforms. No changes were seen in total Wt1 mRNA expression. 
(E) Down-regulation of known WT1 targets correlated with changes in WT1 
isoform abundance. 
*p < 0.05, by Wilcoxon rank sum test. 
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Figure 5. WT1 dysregulation by BaP is Ahr allele specific in D2N-Ahrd/d metanephri, 
as shown by qRT-PCR analysis (see “Materials and Methods” for details). Values 
(mean ± SD) represent 2−∆∆CT normalized fold change relative to the DMSO D2N 
control (shown as a dashed line in E); n ≥ 6 metanephri/group. (A–D) Abundance 
of splice variants [(A) +KTS, (B) –KTS, (C) +17aa, and (D) –17aa)] from BaP-treated 
and DMSO CF7 control samples. Expression of the Ahrd/d allele abrogated BaP-
induced modulation of Wt1 mRNA isoforms in D2N mice. No changes were seen in 
total Wt1 mRNA expression. (E) Down-regulation of known WT1 targets correlated 
with changes in WT1 isoform abundance. 18S, β-actin, and GADPH were run as 
internal controls for all qRT-PCR reactions. While all controls tested demonstrated 
tolerable variability, 18S provided the optimal reproducibility in our assays.
*p < 0.05, by Wilcoxon rank sum test. 
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Discussion
Significant progress has been made in under­
standing the genetic basis of renal develop­
mental disease. Of note is the discovery that 
mice overexpressing the –KTS isoform of Wt1 
have severely compromised renal develop­
ment, increased stromal tissue, decreased 
tubular epithelium and glomeruli, and 
altered podo  cyte structure (Hammes et al. 
2001). Although the exact molecu  lar conse­
quences resulting from alterations of the four 
predominant and biologically rele  vant iso­
forms of WT1 remain to be defined, it is well 
established that the –KTS mRNA encodes 
a protein that participates in transcriptional 
regulation, whereas the protein encoded by 
+KTS mRNA associates with splicing factors 
(Hastie 2001). Here we present evidence that 
BaP induces shifts in –KTS that correlate with 
down­regulation of differentiation markers.   
The actions of BaP are likely mediated by 
unregulated activation of AHR signaling dur­
ing nephro  genesis and involve the classical 
AHR–HIF1β macro  molecular complex or 
molecu  lar inter  actions with NF­κB (nuclear 
factor κB), activator protein 1 (AP­1), and/or   
glucocorticoid receptor (Nanez and Ramos 
2010). Of relevance are reports show­
ing that the glucocorticoid receptor associ­
ates with peroxisome proliferator­activated 
receptor gamma coactivator­1 (PGC­1), a 
known regulator of cotranscriptional splic­
ing (Knutti et al. 2001). Another possibil­
ity involves direct binding of AHR to the 
Wt1 promoter, which contains two consensus 
AHR­responsive elements within a regula­
tory region known to regulate transcription­
coupled splicing events (Cohen et al. 1997). 
Because AHR associates with proteasomal 
complexes consisting of damaged­DNA­
binding protein 1, aryl hydrocarbon receptor 
nuclear translocator, transducin­β­like 3, and 
cullin 4B and itself possesses E3 ligase activity 
(Ohtake et al. 2007), AHR may regulate pro­
teasomal degradation of factors required for 
Wt1 splicing. Although the E3 ligase activ­
ity of AHR has not been fully characterized, 
AHR ubiquiti  na  tion occurs in both cyto­
plasm (Song and Pollenz 2002) and nucleus 
(Marlowe and Puga 2010). 
A model detailing a constitutive function 
for AHR in the regulation of nephro  genesis via 
WT1 is further supported by our finding that 
use of the genetically resistant D2N strain, 
which expresses the Ahrd allele or competitive 
antagonists of AHR, prevented renal develop­
mental deficits in BaP­treated metanephri and 
restored normal ratios of Wt1 mRNA iso­
forms. The modulation of renal differentiation 
markers in organ culture induced by BaP is 
consistent with the deficits in kidney morpho­
genesis observed after intr  auterine exposure 
to BaP and with mounting evidence impli­
cating AHR in the regulation of prolifera­
tion, develop  ment, adhesion, migration, and 
proteasomal degradation of several organ sys­
tems (Nanez and Ramos 2010). Mutation of 
the ligand­binding domain in the Ahrd allele 
decreases ligand­binding affinity by 10­fold 
compared with Ahrb-1 and decreases nuclear 
translocation efficiency, transcriptional activa­
tion, and degradation upon ligand binding 
(Poland et al. 1994). Likewise, α­NF does not 
elicit the conforma  tional changes necessary for 
efficient trans  loca  tion and/or protein degrada­
tion (Henry and Gasiewicz 2003). Ahr­null 
mice exhibit delayed nephro  genesis and com­
promised renal develop  ment (Falahatpisheh 
and Ramos 2003) and a hyper  tensive pheno­
type (Lund et al. 2003, 2006), so the renal 
pheno  type of Ahr­null mice, as well as that 
of mice treated in utero with BaP, may be 
Figure 6. BaP inhibits nephro  genesis via an Ahr allele–specific mechanism, as shown by glomeru  lar number 
normalized per area (mean ± SD; A) and photomicrographs of eosin-stained cross sections (bars = 200 μm; 
B) from kidneys resected from 7-day old C57b1/b1 and D2N-AHRd/d mice exposed to 0.1 or 0.5 mg/kg BaP or 
MCT oil vehicle in utero (see “Materials and Methods” for details). g, glomeruli. Bars = 200 μm. 
*p < 0.05 compared with MCT, by ANOVA and LSD post hoc tests. 
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mediated by interference with develop  mental 
programming at the meta  nephric stage of 
renal cell differentiation. Together, our find­
ings implicate AHR as a key regulator of renal 
morpho  genesis and differentiation and suggest 
that exogenous ligands of AHR alter genetic 
programming of the kidney during critical 
periods of development.
The disruption of nephro  genesis by BaP 
involved changes in expression of epithelial 
markers of differentiation. Sfrp1 is a mesen­
chymal marker expressed in the metanephric 
medullary and cortical stroma that acts as a 
regulator of branching morpho  genesis and 
tubule formation (Yoshino et al. 2001). Igf2r 
is expressed during early nephro  genesis, 
whereas Igf1r is expressed ubiquitously 
throughout renal maturation (Duong Van 
Huyen et al. 2003), and loss of either recep­
tor compromises renal growth and differen­
tiation (Feld and Hirschberg 1996). Wnt4 
is expressed in condensed mesenchyme and 
pre  tubular aggregates (Vainio et al. 1999), and 
Wnt4 deficiency inhibits tubule develop  ment 
(Stark et al. 1994). Lhx1 is chiefly expressed 
in the ureteric bud and induced in mesenchy­
mal aggregates and differentiating comma­ 
and S­shaped bodies (Barnes et al. 1994; 
Karavanov et al. 1998), and murine models of 
Lhx1 deficiency are born headless and without 
kidneys despite the presence of other organs 
(Shawlot and Behringer 1995). Lhx1­null mice 
do not progress past mesonephric development 
(Shawlot and Behringer 1995). E­cadherin is a 
general marker of mesynchemal­to­epithelial 
cell transition that is expressed in the ureteric 
bud epithelium, distal tubule progenitor cells, 
and most differentiated tubular epithelium 
(Cho et al. 1998). E­cadherin–null mice 
show decreased nephrons due to a failure of 
proper fusion of metanephric mesenchyme to 
the ureteric bud (Mah et al. 2000). The criti­
cal functions executed by these genes during 
metanephric differentiation and the disrup­
tion of coordinated patterns of gene expression 
induced by BaP in an AHR­specific manner 
further implicate the AHR as a critical regula­
tor of renal cell differentiation.
Fetal programming is a process whereby 
during a critical window of develop  ment a 
stimulus induces lasting effects on the struc­
ture or function of the organism (Barker 
2004). The evidence we present here shows 
that intra  uterine exposure to BaP during 
nephro  genesis is associated with sustained 
deficits of renal structure and function that 
compromise organ function long after birth. 
These observations are consistent with pre­
vious correlations linking low birth weight 
(LBW) and smoking with the disruption of 
renal develop  mental programming. LBW 
humans have reduced nephron numbers and 
glomerular hypertrophy and are prone to 
micro  albuminuria, proteinuria, and decreased 
glomerular filtration (Celsi et al. 1998; 
Nwagwu et al. 2000; Sanders et al. 2005). 
Reduced renal capacity leads to glomeru  lar 
hyper  tension and compensatory hypertro­
phy, which in turn is associated with disrup­
tion of the glomerular basement membrane 
and glomerulo  sclerosis. Sustained glomeru­
lar injury exacerbates nephron loss, further 
reducing renal glomerular filtration rate. A 
reduction in renal capacity further increases 
blood pressure and completes a futile cycle of 
glomerulo  sclerosis and nephron loss that may 
ultimately result in progressive renal failure 
(Zandi­Nejad et al. 2006).
Our model in which maternal BaP insult 
results in decreases in podocyte numbers 
that impair glomerular filtration is strikingly 
similar to clinical manifestations seen in 
conditions such as focal segmental glomerulo  ­
sclerosis or diabetic nephropathy (Hara et al. 
2001; Hayden et al. 2005; Kim et al. 2001; 
Wolf et al. 2005). Podocytes are terminally 
differentiated cells that line the glomeru  lar 
basement membrane and act as a size­selective 
Figure 7. BaP exposure induces glomerular-specific injury, as shown by albumin (A,B), podocyte number (C), 
and total WT1 signal (D) in urine collected from 52-week-old C57b1/b1 and D2N-AHRd/d mice exposed to 0.1 or 
0.5 mg/kg BaP or MCT oil in utero (see “Materials and Methods” for details). (A) Expression of the Ahrd/d 
allele abrogates BaP-induced alterations in albumin urinary levels in C57 mice compared with D2N mice. 
(B) Silver stain visualization of mouse urinary albumin in C57 mice exposed in utero to 0.5 mg/kg MCT or BaP. 
(C) Immunohistochemical analysis of podocyte numbers quantified using WT1 signal filtered for intensity, 
color, and size normalized to glomerular density. (D) Immunohistochemical analysis of total WT1 signal quan-
tified using WT1 normalized to podocyte numbers. For A, C, and D, data are mean ± SD. 
*p < 0.05 compared with the corresponding MCT control, by ANOVA and LSD post hoc tests. 
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filter that must structurally encompass the 
entire glomerular surface with foot processes 
to maintain proper filtration (Wiggins 2007). 
Podocytopenia results in denudation of the 
basement membrane that compromises glom­
erular function to initiate a cycle of injury and 
continued podocyte loss, leading to progres­
sive renal failure. In fact, glomerulopathies are 
the most common causes of end­stage renal 
disease worldwide (Hricik et al. 1998).
Conclusions
The discovery of novel functions of AHR 
during nephro  genesis highlights a potential 
mechanism for compromised renal develop­
ment after disruption of AHR signaling in 
pregnant women exposed to tobacco smoke 
or babies exposed post  natally to second­hand 
smoke. Such bioavailability of poly  cyclic aro­
matic hydro  carbons provides a ready source for 
agents that modify early determinants of renal 
cell differentiation. Of relevance are studies 
linking AHR genetic poly  morphisms to tobac­
co­smoke–induced decreases in birth weight 
(Sasaki et al. 2006), along with associated 
microalbuminuria, proteinuria, and height­
ened risk of end­stage renal disease (Zandi­
Nejad et al. 2006). Other stressors, such as 
diet and environmental exposures, are associ­
ated with LBW and deficits in renal develop­
ment (Everson et al. 1988; Nelson et al. 1999; 
Roquer et al. 1995; Zandi­Nejad et al. 2006). 
In humans, strong associations have been 
reported between smoking and albuminuria 
in non    diabetic patients (Pinto­Sietsma et al. 
2000) and a higher risk of renal dys  function 
and renal cancer (Bertazzi et al. 1989). The 
protection afforded in mice by Ahrd suggests 
that the risk of AHR­mediated renal develop­
mental deficits is most likely relevant in sub­
jects expressing poly  morphic variants of AHR 
with increased ligand affinity. Such deficits are 
not severe but instead may compromise renal 
reserve capacity, leading to increased suscepti­
bility to late­onset renal disease.
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